Literature DB >> 33559286

Regarding "Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era".

Marco Picardi1, Claudia Giordano1, Roberta Della Pepa1, Novella Pugliese1, Aldo Leone1, Giuseppe Delle Cave1, Rossella Iula1, Fabrizio Pane1, Giuseppe Gentile2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33559286      PMCID： PMC8176981          DOI： 10.1002/onco.13710

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  5 in total

1.  Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL.

Authors:  Marco Picardi; Roberta Della Pepa; Claudia Giordano; Irene Zacheo; Novella Pugliese; Chiara Mortaruolo; Fabio Trastulli; Antonio Giordano; Mariano Lucignano; Maria Di Perna; Marta Raimondo; Claudia Salvatore; Fabrizio Pane
Journal:  Blood       Date:  2018-12-07       Impact factor: 22.113

2.  Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era.

Authors:  Chieh-Lung Cheng; Sheng-Chuan Huang; Jia-Hong Chen; Chao-Hung Wei; Wei-Quan Fang; Tung-Hung Su; Chang-Tsu Yuan; Jia-Hau Liu; Ming-Kai Chuang; Hwei-Fang Tien
Journal:  Oncologist       Date:  2020-04-27

3.  Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.

Authors:  Bertrand Coiffier; Catherine Thieblemont; Eric Van Den Neste; Gérard Lepeu; Isabelle Plantier; Sylvie Castaigne; Sophie Lefort; Gérald Marit; Margaret Macro; Catherine Sebban; Karim Belhadj; Dominique Bordessoule; Christophe Fermé; Hervé Tilly
Journal:  Blood       Date:  2010-06-14       Impact factor: 22.113

4.  Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma.

Authors:  Maria Guarino; Marco Picardi; Anna Vitello; Novella Pugliese; Matilde Rea; Valentina Cossiga; Fabrizio Pane; Nicola Caporaso; Filomena Morisco
Journal:  Ann Hepatol       Date:  2017 March-April       Impact factor: 2.400

5.  Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin.

Authors:  Lijuan Deng; Yuqin Song; Ken H Young; Shimin Hu; Ning Ding; Weiwei Song; Xianghong Li; Yunfei Shi; Huiying Huang; Weiping Liu; Wen Zheng; Xiaopei Wang; Yan Xie; Ningjing Lin; Meifeng Tu; Lingyan Ping; Zhitao Ying; Chen Zhang; Yingli Sun; Jun Zhu
Journal:  Oncotarget       Date:  2015-09-22
  5 in total
  1 in total

1.  Risk of Non-Hodgkin Lymphoma among Patients with Hepatitis B Virus and Hepatitis C Virus in Taiwan: A Nationwide Cohort Study.

Authors:  Yung-Rung Lai; Ya-Lan Chang; Chiu-Hsiang Lee; Tung-Han Tsai; Kuang-Hua Huang; Chien-Ying Lee
Journal:  Cancers (Basel)       Date:  2022-01-24       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.